Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,552Revenue $M16,671Net Margin (%)14.8Z-Score3.2
Enterprise Value $M43,641EPS $4.6Operating Margin %16.8F-Score5
P/E(ttm))20.3Cash Flow Per Share $5.6Pre-tax Margin (%)15.1Higher ROA y-yN
Price/Book4.510-y EBITDA Growth Rate %10.9Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %5.8Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %3.4ROA % (ttm)11.7Higher Current Ratio y-yN
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)35.7Less Shares Outstanding y-yY
Payout Ratio %58.0Shares Outstanding M542ROI % (ttm)15.1Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXRichard Pzena 2014-12-31 Buy 1.5%$67.24 - $74.7
($71.71)
$ 69.21-4%New holding, 3944140 sh.3,944,140
BAXRay Dalio 2014-12-31 Add$67.24 - $74.7
($71.71)
$ 69.21-4%Add 36.29%25,163
BAXJoel Greenblatt 2014-12-31 Buy $67.24 - $74.7
($71.74)
$ 69.21-4%New holding, 5186 sh.5,186
BAXBill Nygren 2014-12-31 Sold Out -0.75%$67.24 - $74.7
($71.74)
$ 69.21-4%Sold Out0
BAXJean-Marie Eveillard 2014-12-31 Reduce-0.06%$67.24 - $74.7
($71.71)
$ 69.21-4%Reduce -32.14%676,637
BAXMario Gabelli 2014-12-31 Reduce-0.02%$67.24 - $74.7
($71.71)
$ 69.21-4%Reduce -23.14%172,900
BAXDavid Dreman 2014-09-30 Buy 0.02%$71.28 - $77
($74.81)
$ 69.21-8%New holding, 3397 sh.3,397
BAXRay Dalio 2014-09-30 Add0.01%$71.28 - $77
($74.81)
$ 69.21-8%Add 220.37%18,463
BAXRobert Olstein 2014-09-30 Sold Out -0.59%$71.28 - $77
($74.81)
$ 69.21-8%Sold Out0
BAXJean-Marie Eveillard 2014-06-30 Add0.18%$71.98 - $75.45
($73.67)
$ 69.21-6%Add 90872.4%1,000,696
BAXJohn Keeley 2014-06-30 Buy 0.05%$71.98 - $75.45
($73.67)
$ 69.21-6%New holding, 37150 sh.37,150
BAXScott Black 2014-06-30 Reduce-0.43%$71.98 - $75.45
($73.67)
$ 69.21-6%Reduce -30.98%123,976
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$71.98 - $75.45
($73.67)
$ 69.21-6%Sold Out0
BAXRay Dalio 2014-06-30 Reduce-0.03%$71.98 - $75.45
($73.67)
$ 69.21-6%Reduce -90.74%5,763
BAXJohn Hussman 2014-06-30 Reduce-0.02%$71.98 - $75.45
($73.67)
$ 69.21-6%Reduce -50%3,725
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$71.98 - $75.45
($73.67)
$ 69.21-6%Sold Out0
BAXCharles Brandes 2014-03-31 Buy 0.19%$66.49 - $72.85
($68.75)
$ 69.211%New holding, 204560 sh.204,560
BAXScott Black 2014-03-31 Add0.17%$66.49 - $72.85
($68.75)
$ 69.211%Add 13.41%179,629
BAXDavid Dreman 2014-03-31 Buy 0.01%$66.49 - $72.85
($68.77)
$ 69.211%New holding, 2453 sh.2,453
BAXJean-Marie Eveillard 2014-03-31 Reduce$66.49 - $72.85
($68.77)
$ 69.211%Reduce -85.53%1,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BAX Joel Greenblatt 2014-12-315,18600New Buy
BAX Richard Pzena 2014-12-313,944,1400.731.5New Buy
BAX Ray Dalio 2014-12-3125,16300.02+36.29%
BAX Charles Brandes 2014-12-31238,0730.040.25+5.8%
BAX Scott Black 2014-12-31130,1360.021.3+4.66%
BAX John Keeley 2014-12-3142,1100.010.06+3.59%
BAX David Dreman 2014-12-313,50400.02+3.15%
BAX Dodge & Cox 2014-12-313,38200
BAX John Hussman 2014-12-313,72500.03
BAX John Rogers 2014-12-3162,9510.010.05-0.16%
BAX Tweedy Browne 2014-12-312,572,3390.474.8-0.35%
BAX Mario Gabelli 2014-12-31172,9000.030.07-23.14%
BAX Jean-Marie Eveillard 2014-12-31676,6370.120.12-32.14%
BAX Bill Nygren 2014-12-31000Sold Out
BAX Meridian Funds 2013-06-308,60000.02
Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HELLMAN PETER SDirector 2015-02-06Sell4,830$71.32-2.66view
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-7.32view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-9.82view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-9.63view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-8.66view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-6.71view
Shapazian Carole JDirector 2014-05-02Sell5,680$75.28-7.78view
STROUCKEN ALBERT P LDirector 2014-04-24Buy696$67.522.81view
STORM KEES JDirector 2014-04-23Sell5,760$72.45-4.18view
Devitt Blake EDirector 2014-04-21Sell4,334$73.12-5.06view

Press Releases about BAX :

Quarterly/Annual Reports about BAX:

News about BAX:

Articles On GuruFocus.com
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Best Stock Pick For Long Term Investors Feb 10 2015 
Richard Pzena's New Buys Feb 09 2015 
Richard Pzena's 5 New Q4 Stock Buys Feb 06 2015 
Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 
Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 


More From Other Websites
Final Glance: Pharmaceuticals companies Mar 03 2015
Final Glance: Medical Devices companies Mar 03 2015
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog Mar 03 2015
Midday Glance: Medical Devices companies Mar 02 2015
Midday Glance: Pharmaceuticals companies Mar 02 2015
Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog Feb 27 2015
Early Glance: Pharmaceuticals companies Feb 27 2015
Early Glance: Medical Devices companies Feb 27 2015
Ameren (AEE) Earnings Report: Q4 2014 Conference Call Transcript Feb 25 2015
Nektar Therapeutics Incurs Narrower-than-Expected Q4 Loss - Analyst Blog Feb 25 2015
Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog Feb 24 2015
Baxter Selects Bannockburn, Ill., Facility as Location for Baxalta Global Headquarters Feb 23 2015
Baxter Selects Bannockburn, Ill., Facility as Location for Baxalta Global Headquarters Feb 23 2015
Baxter to Present at Barclay’s Global Healthcare Conference Feb 22 2015
The 52-Week Low Club for Friday Feb 20 2015
Baxter to Present at Barclay’s Global Healthcare Conference Feb 19 2015
Zacks Rank #5 Additions for Thursday - Tale of the Tape Feb 19 2015
Baxter Dividend Unsustainable, But Don't Fear The Cut: JPMorgan Feb 18 2015
Momenta (MNTA) Posts Wider-than-Expected Loss in Q4 - Analyst Blog Feb 18 2015
Baxter Declares Quarterly Dividend Feb 17 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 8 months ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK